A model for the turnover of dihydrotestosterone in the presence of the irreversible 5α-reductase inhibitors GI198745 and finasteride

Clinical Pharmacology and Therapeutics

Volumn 64, Issue 6, 1998, Pages 636-647

  Gisleskog, Per Olsson ^a   Hermann, David ^b   Hammarlund Udenaes, Margareta ^b   Karlsson, Mats O ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; DUTASTERIDE; FINASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ANDROGEN RELEASE; ARTICLE; AUTOPSY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG ELIMINATION; DRUG POTENCY; ENZYME INHIBITION; HUMAN; MALE; MODEL; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADULT; AZASTEROIDS; DIHYDROTESTOSTERONE; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; MIDDLE AGED; REFERENCE VALUES; SINGLE-BLIND METHOD; TESTOSTERONE; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 0032424543     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90054-6     Document Type: Article

References (22)

1. Girman CJ, Kolman C, Liss CL, Bolognese JA, Binkowitz BS, Stoner E. Effects of finasteride on health-related quality of life in men with symptomatic benign prostatic hyperplasia: finasteride study group. Prostate 1996;29:83-90.
2. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474-9.
3. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991;338:469-71.
4. Lange PH. Is the prostate pill finally here? N Engl J Med 1992;327:1234-6.
5. Russell DW, Wilson JD. Steroid 5α-reductase: two genes/two enzymes. Annu Rev Biochem 1994;63:25-61.
6. Jenkins EP, Andersson S, Imperato-McGinley J, Wilson JD, Russell DW. Genetic and pharmacological evidence for more than one human steroid 5α-reductase. J Clin Invest 1992;89:293-300.
7. Vermeulen A, Giagulli VA, De Schepper P, Buntinx A, Stoner E. Hormonal effects of an orally active 4-azasteroid inhibitor of 5α-reductase in humans. Prostate 1989;14:45-53.
8. Gormley G, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992;327:1185-91.
9. Moore E, Bracken B, Bremner W, et al. Proscar: five-year experience. Eur Urol 1995;28:304-9.
10. Steiner JF. Clinical pharmacokinetics and pharmacodynamics of finasteride. Clin Pharmacokinet 1996;30:16-27.
11. Tian G, Mook RA, Moss ML, Frye SV. Mechanism of time-dependent inhibition of 5α-reductases by delta 1-4-azasteroids: toward perfection of rates of time-dependent inhibition by using ligand binding energies. Biochemistry 1995;34:13453-9.
12. Bramson HN, Hermann D, Batchelor KW, Lee FW, James MK, Frye SV. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharm Exp Ther 1997;282:1496-502.
13. Faller B, Farley D, Nick H. Finasteride: a slow-binding 5α-reductase inhibitor. Biochemistry 1993;32:5705-10.
14. Tian G, Chen S, Facchine KL, Prakash SR. Chemical mechanism of the covalent modification of 5α-reductases by finasteride as probed by secondary tritium isotope effects. J Am Chem Soc 1995;117:2369-70.
15. Ko HC, Jusko WJ. Pharmacodynamic modeling of finasteride, a 5α-reductase inhibitor. Pharmacotherapy 1995; 15:509-11.
16. Morris DM, Grosse CM, Selinger KA. Determination of GI198745 in human serum by LC/APCI/MS [abstract]. Proceedings of the 6th International Symposium for Pharmaceutical and Biomedical Analysis (PBA), St Louis (MO); April 23-26, 1995. Amsterdam: Elsevier Science; 1995.
17. Olsson Gisleskog P, Hermann D, Hammarlund-Udenaes M, Karlsson MO. The pharmacokinetic modeling of GI198745, a compound with parallel linear and non-linear elimination. Br J Clin Pharmacol [in press].
18. Johnsson EN, Karlsson MO. Xpose: an Splus based model building aid for population analysis with NON-MEM. In: Aarons L, Balant LP, Danhof M, et al, editors. The population approach: measuring and managing variability in response, concentration and dose. Brussels: The European Commission; 1997. p. 411-3.
19. Winchell GA, Gregoire S, Constanzer ML. Pharmacokinetics and oral bioavailability of the 5α-reductase inhibitor finasteride in man [abstract]. Pharmacol Res 1997;7:s251.
20. Imperato-McGinley J. 5α-metabolism in finasteride-treated subjects and male pseudohemaphrodites with inherited 5α-reductase deficiency. Eur Urol 1991;20 (suppl):78-81, 78-81.
21. Tian G, Stuart JD, Moss ML, et al. 17β-(N-tert-butylcarbamoyl)-4-aza-5α-androstan-1-en-3-one is an active site-directed slow time-dependent inhibitor of human steroid 5α-reductase 1. Biochemistry 1994;33:2291-6.
22. Gormley G, Stoner E, Rittmaster RS, et al. Effects of finasteride (MK-906), a 5α-reductase inhibitor, on circulating androgens in male volunteers. J Clin Endocrinol Metab 1990;70:1136-41.